Published online Jan 16, 2024. doi: 10.12998/wjcc.v12.i2.314
Peer-review started: November 3, 2023
First decision: November 16, 2023
Revised: December 6, 2023
Accepted: December 28, 2023
Article in press: December 28, 2023
Published online: January 16, 2024
Processing time: 69 Days and 1.9 Hours
Lung cancer and coronary heart disease (CHD) have become the major diseases worldwide and often occur simultaneously in the same patient. This comorbidity poses great challenges for treatment, especially for those patients who underwent percutaneous coronary intervention (PCI). Therefore, it has important theoretical and practical implications to explore how to improve the prognosis and quality of life of such patients through continuous care.
The concerns of the complex physical and mental problems that patients face during the course of their disease, and the potential importance of continuous care in clinical practice in improving patient quality of life.
This study aims to explore the impact of continuous care in patients with lung cancer and CHD undergoing PCI.
Continuous care was provided in the intervention group and the usual care in the control group.
There were significant differences between the groups in left ventricular ejection fraction, 6-min walking test, oxygen uptake, quality of life, and medication adherence (P < 0.05). The improvement was more significant in the intervention group compared to the control group. Higher in the intervention group than the control group, and the difference was statistically significant (P < 0.05).
After PCI, patients with CHD with lung disease may benefit from continuity of care, including cardiac and pulmonary function, medication adherence, and quality of life.
By exploring in depth the impact of continuous care in patients with PCI lung cancer with CHD, we expect to provide more effective treatment strategies and care options for clinicians and caregivers, which thus improve patient outcomes and quality of life.